XNAS
DFTX
Market cap2.58bUSD
Oct 08, Last price
34.18USD
1D
-2.59%
1Q
-27.38%
IPO
259.58%
Name
Mind Medicine (MindMed) Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
38.16%
Rev. gr., 5y
%
Revenues
0
Net income
-184m
L+69.12%
CFO
-132m
L+66.26%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Key people
Carol Vallone
Independent Chairman of the Board · since 2021
Chief Financial Officer · since 2025
Daniel Karlin
Chief Medical Officer · since 2021
Gregg Pratt
Chief Regulatory and Quality Assurance Officer · since 2024
Chief Commercial Officer · since 2025
Mark Sullivan
Chief Legal Officer, Corporate Secretary · since 2023
Director · since 2026
Robert Barrow
Chief Executive Officer, Director · since 2021
Suzanne Bruhn
Independent Director · since 2022
Roger Crystal
Independent Director · since 2022
Independent Director · since 2023
Andreas Krebs
Independent Vice Chairman of the Board · since 2021
Legal address
700 West Georgia Street
Suite 2500
Vancouver, BC V7Y 1B3
CA
Suite 2500
Vancouver, BC V7Y 1B3
CA
Headquarters
One World trade Center
Suite 8500
New York, NY 10007
US
Suite 8500
New York, NY 10007
US
Previous name
BROADWAY GOLD MINING LTD.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑08 | 2018‑08 | 2017‑08 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||